The document discusses the global tobacco epidemic through the lens of the European region. It provides background on the WHO Framework Convention on Tobacco Control (FCTC), including its origins in 1996 and adoption in 2003. As of 2016, there were 180 parties to the FCTC, including 179 countries and the EU. The document also shows statistics on tobacco control policies and current tobacco use prevalence in Europe and globally. It concludes by discussing targets for reducing tobacco and other non-communicable disease risk factors by 2025 and 2030 as part of the UN Sustainable Development Goals.
Overview of Tobacco Treatment Provisions at a National Level -- Martin RawGlobal Bridges
Presentation by Martin Raw, UK Centre for Tobacco Control Studies and National Institute of Alcohol and Drug Policies, Brazil, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Proposed Changes to How E-Cigarettes Are Regulated - Prof. Linda BauldLindsay Fox
Proposed changes to how e-cigarettes are regulated: UK and EU context
Slides from Prof. Linda Bauld's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
E-Cigarette Summit Speaker: Dr Lynne DawkinsLindsay Fox
Slides from Dr Lynne Dawkins' presentation at the E-Cigarette Summit, London November 12, 2013. Electronic Cigarettes: What are they, and are they effective?
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Slides on the current situation with global cigarette consumption and trends, and how new nicotine products could change things.
See blog at: http://www.clivebates.com/?p=2782 for more commentary.
Presentation delivered by Dr Eibhlin Connolly, Deputy Chief Medical Officer at the Department of Health and Children at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
FDLI - Lesson for the US from other jurisdictions - the United Kingdom -29 Oc...Clive Bates
Presentation on the most significant differences between US and UK/EU regulation of tobacco and vaping products. FDLI Tobacco and Nicotine Products Regulation and Policy Conference
Overview of Tobacco Treatment Provisions at a National Level -- Martin RawGlobal Bridges
Presentation by Martin Raw, UK Centre for Tobacco Control Studies and National Institute of Alcohol and Drug Policies, Brazil, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Proposed Changes to How E-Cigarettes Are Regulated - Prof. Linda BauldLindsay Fox
Proposed changes to how e-cigarettes are regulated: UK and EU context
Slides from Prof. Linda Bauld's presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
E-Cigarette Summit Speaker: Dr Lynne DawkinsLindsay Fox
Slides from Dr Lynne Dawkins' presentation at the E-Cigarette Summit, London November 12, 2013. Electronic Cigarettes: What are they, and are they effective?
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Slides on the current situation with global cigarette consumption and trends, and how new nicotine products could change things.
See blog at: http://www.clivebates.com/?p=2782 for more commentary.
Presentation delivered by Dr Eibhlin Connolly, Deputy Chief Medical Officer at the Department of Health and Children at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
FDLI - Lesson for the US from other jurisdictions - the United Kingdom -29 Oc...Clive Bates
Presentation on the most significant differences between US and UK/EU regulation of tobacco and vaping products. FDLI Tobacco and Nicotine Products Regulation and Policy Conference
BlueBerryAsia having Humel Vidyut Portable Generator provide in India. This is very new technique for instant electricity with 100% mobility. For product details pl call on +911130446418, sales@blueberryasia.com
Ello: some suggestion for even better user experienceTobias Limbach
We like Ello! Beautiful design meets beautiful content. But sime small things can be improved, to deliver an even better user experience. Here are some suggestions.
Joachim Schüz - A Review of the European Code against CancerIrish Cancer Society
Joachim Schüz, Head of the Section of Environment and Radiation at the International Agency for Research on Cancer, spoke about the latest review of the European Code against Cancer at the European Week Against Cancer in Dublin, Ireland on May 29th, 2013.
Are Electronic Cigarettes good for Tobacco Control in Ireland - Prof Luke Clancy
IPH, Open, Conference, Belfast, Northern, Ireland, Dublin, Titanic, October, 2014, Public, Health
Electronic Cigarette Regulations: When Less is Moreecigarettesummit
Clive Bates, speaker at E-Cigarette Summit London, discusses regulations surrounding electronic cigarettes. He points out that tight regulations could harm the e-cig industry and push people back to smoking tobacco. Visit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
Presentation by Anca Toma Friedlaender (Senior Policy Advisor, Smoke Free Partnership) on the occasion of the EESC hearing on Manufacture, presentation and sale of tobacco and related products (Brussels, 19 Feb 2013).
Regulation: why less is more... E-cigarette Summit 12 November 2013 - Clive B...Clive Bates
My presentation covering why 'less is more' when it comes to regulating low risk alternatives to cigarettes such as e-cigarettes. Too much regulation will limit appeal, increase costs, raise barriers to entry and inhibit innovation. I also urge a focus on the huge potential benefits of low-risk alternatives to smoking instead of obsession over minor or implausible risks.
Similar to Global tobacco epidemic through the European lens (20)
Science of Flavors in Tobacco Products Sept 2023UCT ICO
This seminar aims to unravel the role of flavoring agents in enhancing the appeal of inhalable tobacco and nicotine products. Flavors are present in almost all tobacco/nicotine products and play a crucial role in their appeal and use behaviors but are poorly regulated. Dr. Krishnan-Sarin will discuss the sensory processes underlying the perception of flavoring agents, known pharmacological targets for flavor chemicals, and evidence of the potential toxicity of flavoring agents. She will also highlight the implications of the state of the science of flavoring agents for future research and regulation.
Developing the evidence base for an intervention to address tobacco and canna...UCT ICO
Why tobacco and cannabis? High smoking rates amongst those with SUD (Guydish et al, 2016)
Used together but clinically separated
Unintended consequence of tobacco addiction
Poorer cessation outcomes for co-users (Peters et al, 2012)
Increasing concern about impact of cannabis use; potency increased (EMCDDA, 2018, Freeman et al 2018, 2019)
Unique, complex relationship
La importancia del empaquetado en el consumo de los productos del tabaco: inv...UCT ICO
Juan Miguel Rey-Pino
Departamento de Comercialización e Investigación de Mercados
Universidad de Granada
Blanca Lacave-García
Departamento de Marketing y Comunicación
Universidad de Cádiz
Propuesta para empaquetado neutro en MéxicoUCT ICO
El Dr. Horacio Rubio (UNAM) hace una magistral disertación sobre la importancia del control del tabaquismo y qué posibles pasos aún no se han implementado. También hacer un repaso de la situación del tabaquismo en México
From partial to complete smoking bans -what we have learned in spain UCT ICO
Presentation of the lessons learned by the Tobacco Unit of the Catalan Institut of Oncology on tobacco partial bans:
It is better a total ban than a partial one. But if partial bans cannot be avoided, they have to be a first step towards total bans.
Partial bans can be changed thorough action(s) joining scientists, consumers, policitians... Constant presence in mass media, forums, debates and creating alliances with policy decisors. It is not “a day” effort but a long-term run prevention of regressive changes after total bans.
UCSF-CTCRE 13th September 2013
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
5. Resolution WHA 49.17
International framework convention
on tobacco control
sponsored by Canada
first mention in the WHA of a treaty
Where it all began- May 1996- Introduction of the concept of the WHO FCTC
6. "We invite the Member
States of WHO to initiate
work on a Framework
Convention –
to take the first step in a
process that the World
Health Assembly
has called for before."
May 1998- Dr Bruntland, former Director General, at the World Health Assembly
14. Name of presentation
Date of presentation
Current tobacco use in Europe
No room for complacency
WHO Region
Male
prevalence
Female
prevalence
Both sexes
EUR 38% 19% 28%
WPR 47% 3% 25%
EMR 38% 4% 22%
AMR 26% 16% 20%
SEAR 34% 4% 19%
AFR 22% 7% 15%
Global 36% 8% 22%
16. Halt the rise in
diabetes and
obesity
A 10% relative
reduction in
prevalence of
insufficient
physical activity
At least a 10%
relative
reduction in
the harmful
use of alcohol
A 25% relative reduction in
risk of premature mortality
from cardiovascular disease,
cancer, diabetes or chronic
respiratory diseases
An 80%
availability of
the affordable
basic
technologies
and essential
medicines
A 30% relative
reduction in
prevalence of
current tobacco
use
A 30%
relative
reduction in
mean
population
intake of
salt/sodium
A 25% relative
reduction in
prevalence of
raised blood
pressure or
contain the
prevalence of
raised blood
pressure
At least 50%
of eligible
people receive
drug therapy
and
counselling to
prevent heart
attacks and
strokes
SDG targets for 2030 are aligned with the NCD targets for 2025
17. Goal 3: Ensure healthy lives and
promote wellbeing for all people
at all ages
Commits governments to develop national
responses:
• Target 3.4: By 2030, reduce by one
third premature mortality from NCDs
• Target 3.a: Strengthen the
implementation of the WHO
Framework Convention on Tobacco
Control
Tobacco control in the 2030 Agenda for Sustainable Development
18. Prevalence (%) of current tobacco smoking (15+) in Europe
from 2000 with projections to 2025
0
10
20
30
40
50
60
2000 2005 2010 2015 2020 2025
Males Both Females
Good morning
I would like, together with you, to look into:
- WHO FCTC, where are we coming from?
Status of the WHO FCTC implementation in the European Region, where are we in 2016?
Zoom in to art 5.3. of the WHO FCTC and ask from ourselves, do we need to say same things over and over again?
End by asking what next?
It is 20 years ago the idea of a possible tobacco control treaty was put forward in the context of WHO, in 1996. It has been a long way and carefully crafted process.
4
5
6
7
8
9
Where are we in 2016 in Europe? 20 years after the first idea of a treaty at the WHA and slightly more than 10 years after the entry into force of the WHO FCTC.
Looking at European rates of smoking in the global context, comparing the WHO European Region to other 5 Regions, Europe has the highest level of adult smokers in the world, 28%, and by far highest level of female smokers, 19%.
In the global NCDs related commitments, there is a global voluntary target of a 30% relative reduction in tobacco use by 2025, in less than 10 years time.
SDG targets for 2030 are aligned with the NCD targets for 2025, incl. the target related to tobacco use
SDG targets for 2030 are aligned with the NCD targets for 2025, incl. the target related to tobacco use
From 2000 onwards a downward trend is observed in the prevalence of current tobacco smoking among the adult population in the WHO European Region, both in males and females.
In 2015, it is estimated that the prevalence of current tobacco smoking among males is 37%. For females, this percentage will be half less, namely 19%.
At this stage, it is projected that the prevalence level in 2025 among males will be 31% and among females it will be 16%.
Taking the years from 2010 to 2025, this means a projected relative reduction of 22% among the male population, and of 25 % among the female population
The WHO European Region would need to accelerate its efforts in tobacco control in order to achieve the global target of a 30% relative reduction by 2025.
It also goes for all countries in this room as based on the latest DRAFT trends report to be published in early 2017, none of the countries here would achieve the global voluntary target by 2025.